secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2026-08-05T20:19:21+00:00
Accession:  0001193125-26-335192
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q2 2026 revenue up 19% to $119.6M; net loss $83.4M on $161M fair-value charge
--------------------------------------------------------------------------------

- Total revenue $119.6M (+19% YoY); net product sales $51.8M (+46% YoY) driven by IST growth.
- Net loss $83.4M ($1.14 loss per share) due to $161M unfavorable fair-value change in equity investments (Armata).
- Royalty revenue from GSK stable at $59.8M; IST U.S. net product sales $36.6M (+26% YoY).
- Launched Nortiva Bio for long-acting oral drug delivery; XACDURO licensing deal with Dr. Reddy's for emerging markets.
- Repurchased 1.4M shares for $31.4M in Q2; cash $570.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000119312526335192/0001193125-26-335192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000119312526335192/d228097d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-335192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer